GWP GW Pharm.

RNS Number:2946Q
GW Pharmaceuticals PLC
18 March 2008


                             GW Pharmaceuticals plc

                                 AGM Statement

Porton Down, UK, 18 March 2008: Dr. Geoffrey Guy, Chairman of GW Pharmaceuticals
plc, will make the following comments at today's Annual General Meeting:


"In 2008, we have started to build on the achievements of 2007, a year of
important progress for GW. The licence agreement signed in 2007 with Otsuka
secured the future of our lead product, Sativex(R), in the United States, the
world's largest pharmaceutical market, by providing funding for the US
development plan aimed at securing regulatory approval from the Food & Drug
Administration (FDA). Separately, the global cannabinoid research collaboration
signed with Otsuka later in 2007, enabled us to accelerate the development of
our pipeline of new cannabinoid medicines. During 2007, we also secured a
further approval for Sativex in Canada for the treatment of cancer pain and
achieved clarity from the European regulators as to their requirements to gain
approval.


"2008 is a pivotal year in GW's development with the results expected from three
separate late stage trials for Sativex in Europe and the US.  The first of these
is the MS neuropathic pain Phase III trial in Europe which includes a total of
339 patients. This study is complete and on track for database lock shortly with
headline results due in the coming weeks. Separately, the Phase III MS
spasticity trial requested last year by the UK regulatory authority commenced on
time and is recruiting on schedule. These two trials provide us with separate
regulatory filing opportunities for Sativex in Europe over the coming year.


"Progress is also being made under both elements of the Otsuka collaboration.
The Sativex US Phase IIb/III cancer pain study commenced towards the end of 2007
as planned. Other aspects of the Sativex US development plan agreed with the FDA
are also progressing well. Under the cannabinoid research agreement, promising
pre-clinical data is already starting to emerge on a range of novel cannabinoids
within the Central Nervous System (CNS) and oncology fields.


"Separately, our in-house research programme in the field of type 2 diabetes and
related metabolic disorders is also making progress. We recently announced
highly promising results in both pre-clinical pharmacology studies and a Phase I
trial of a new potential cannabinoid treatment, delta-9-tetrahydrocannabivarin
(THCV). Following on from this first study, GW is now preparing to start a Phase
IIa multiple dose study in type 2 diabetic patients in 2008.


"With Sativex now in the regulatory endgame in Europe and in late stage
development in the US, and the wider field of cannabinoid medicines continuing
to grow, we look forward to reporting news of our progress during 2008.

"As announced in the preliminary results, Dr Brian Whittle, Scientific Director
and co-founder, at the age of 75, has chosen not to seek re-election at the AGM
and therefore retires today.  Although Brian has gradually decreased his working
time over the last few years, he played an instrumental role in the development
of GW and will be greatly missed.  I would like to express on behalf of the
Board my sincere gratitude for his contribution to the company."


Enquiries:


GW Pharmaceuticals plc                               (Today) + 44 20 7831 3113
Dr Geoffrey Guy, Executive Chairman              (Thereafter) + 44 1980 557000
Justin Gover, Managing Director

Financial Dynamics                                           + 44 20 7831 3113
David Yates / Ben Atwell


Notes to Editors

About GW

GW was founded in 1998 and listed on the AiM, a market of the London Stock
Exchange, in June 2001. Operating under license from the UK Home Office, the
company researches and develops cannabinoid pharmaceutical products for patients
who suffer from a range of serious ailments, in particular pain and other
neurological symptoms. GW has assembled a team of over 100 scientists with
extensive experience in developing both plant-based prescription pharmaceutical
products and medicines containing controlled substances. GW occupies a world
leading position in cannabinoids and has developed an extensive international
network of the most prominent scientists in the field.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGMUBVNRWOROAAR

Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024

Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024